Arguments in favour of remdesivir for treating SARS-CoV-2 infections

Recomendaciones en el manejo de la pandemia por coronavirus SARS-CoV-2 (Covid-19) en pacientes con trasplante renal

“…Remdesivir: es el profármaco de un análogo de nucleótido con potente actividad in vitro frente a un amplio espectro de virus ARN, como el virus Marburg, virus Ebola, MERS-CoV, virus respiratorio sincitial, virus Nipah y virus Hendra. Su modo de acción se basa en la terminación prematura de la transcripción del ARN viral 17 . Se sugiere que ayuda a reducir la carga viral y mejora los parámetros respiratorios en animales y en modelos in vitro 18 .…”

Structure of replicating SARS-CoV-2 polymerase

“…This RdRp complex is the target for antiviral nucleoside analogue inhibitors, such as remdesivir 6,7 . Remdesivir shows antiviral activity against coronaviruses in cell culture and animals 8 , inhibits coronavirus RdRp 9,10 , and is currently tested in the clinic as a drug candidate for treating COVID-19 patients [11][12][13] .…”

“…The RdRp of SARS-CoV-2 is composed of a catalytic subunit called non-structural protein (nsp) 12 14 , and two accessory subunits, nsp8 and nsp7 5,15 . The structure of the RdRp was recently reported 16 and is highly similar to the RdRp of SARS-CoV 17 , a zoonotic coronavirus that spread into the human population in 2002 1 .…”

COVID‐19: A review of therapeutics under investigation

“…The drug was given to around 400 patients in the Democratic Republic of Congo, and in 1 study no clinical or biochemical adverse effects were attributable to its administration. 19 As COVID-19 entered the United States, patient 0 in Washington State was treated with remdesivir starting on day 7 of illness. 20 Although direct causation is difficult to prove, there were notably decreased SARS-CoV-2 viral loads by nasopharyngeal and oropharyngeal swabs following administration.…”

“…The World Health Organization (WHO) has released general guidelines for managing the illness caused by the virus (COVID- 19), which includes supportive care similar to other viral pneumonias: airway and respiratory support, empiric antibiotics for secondary bacterial infection, and acute respiratory distress syndrome (ARDS) management. 2 While these treatments are thought to offer the best chance of Supervising Editor: Benjamin T. Kerrey, MD, MS.…”